15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $41000 | -$88M | 0.0% | -230461.0% | -39.2% | -31.5% | -$68M | $34M | $44M |
| 2024 | $20000 | -$95M | 0.0% | -515860.0% | -77.0% | -68.2% | — | — | $37M |
| 2023 | $426000 | -$88M | 0.0% | -22518.5% | -45.6% | -42.0% | -$76M | — | $135M |
| 2022 | -$68000 | -$85M | 0.0% | 129029.4% | -45.7% | -40.9% | -$63M | $5M | $111M |
| 2021 | $4M | -$97M | 0.0% | -2197.6% | -48.8% | -44.4% | -$90M | $1M | $190M |
| 2020 | — | -$49M | — | — | -21.7% | -20.0% | -$35M | $2M | $116M |
| 2019 | — | -$21M | — | — | -45.1% | -38.0% | -$10M | $2M | $9M |
| 2018 | — | -$39M | — | — | -81.1% | -71.5% | -$10M | $572770 | $34M |
| 2017 | — | -$46M | — | — | -117.8% | -73.7% | -$20M | $599927 | $9M |
| 2016 | — | -$11M | — | — | -34.4% | -28.9% | — | $525950 | $3M |
| 2015 | — | -$3M | — | — | -8.0% | -17.3% | — | — | $16M |
| 2014 | — | -$10M | — | — | -54.5% | -45.3% | — | — | $19M |
| 2013 | — | -$12M | — | — | -159.7% | -68.4% | — | $3M | $10M |
| 2012 | — | -$5M | — | — | -42.1% | -21.6% | — | $4M | $13M |
| 2011 | $24M | -$4M | 0.0% | -48.3% | -24.0% | -16.7% | -$8M | — | $11M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$23M | — | — | -4.8% | -4.3% | -$24M | $35M | $63M |
| Mar '26 | — | -$23M | — | — | -7.9% | -6.7% | -$21M | $35M | $98M |
| Dec '25 | $26000 | -$27M | 0.0% | -111126.9% | -12.2% | -9.8% | -$19M | $34M | $44M |
| Sep '25 | $5000 | -$19M | 0.0% | -417180.0% | -10.2% | -8.7% | -$12M | $14M | $61M |
| Jun '25 | $5000 | -$22M | 0.0% | -458440.0% | -13.7% | -11.6% | — | $14M | $183M |
| Mar '25 | $5000 | -$20M | 0.0% | -436300.0% | -13.8% | -12.4% | — | — | $49M |
| Dec '24 | $5000 | -$23M | 0.0% | -497320.0% | -18.8% | -16.6% | — | — | $37M |
| Sep '24 | $5000 | -$23M | 0.0% | -495340.0% | -17.1% | -15.5% | — | — | $31M |
| Jun '24 | $5000 | -$25M | 0.0% | -534900.0% | -16.2% | -14.2% | — | — | $57M |
| Mar '24 | $5000 | -$24M | 0.0% | -535880.0% | -14.1% | -13.0% | — | — | $79M |
| Dec '23 | $37000 | -$32M | 0.0% | -90873.0% | -16.3% | -15.0% | -$17M | — | $135M |
| Sep '23 | $362000 | -$21M | 0.0% | -6226.5% | -13.7% | -12.4% | -$20M | $4M | $87M |
| Jun '23 | $6000 | -$16M | 0.0% | -300116.7% | -9.6% | -8.8% | -$19M | $4M | $102M |
| Mar '23 | $21000 | -$20M | 0.0% | -103614.3% | -12.0% | -10.7% | -$19M | $4M | $105M |
| Dec '22 | -$110000 | -$22M | 0.0% | 20994.5% | -11.7% | -10.5% | -$17M | $5M | $111M |
| Sep '22 | $2000 | -$24M | 0.0% | -1237600.0% | -11.5% | -10.4% | -$15M | $5M | $127M |
| Jun '22 | $8000 | -$20M | 0.0% | -254937.5% | -10.3% | -9.6% | -$17M | $2M | $136M |
| Mar '22 | $32000 | -$19M | 0.0% | -60934.4% | -10.5% | -9.4% | -$14M | $2M | $180M |
| Dec '21 | — | -$24M | — | — | -12.0% | -10.9% | -$22M | $1M | $190M |
| Sep '21 | — | -$34M | — | — | -16.0% | -14.1% | -$18M | $2M | $175M |
How the market has priced ALT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Altimmune, Inc.'s revenue has declined 68.9% per year. These are computed facts, not advice.
As of FY2025, Altimmune, Inc. reported $34M of total debt against $44M of cash; operating income covered interest expense -57.8×.
In FY2025, gross margin was —, operating margin -230461.0%, and net margin -214861.0%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.